G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis

G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis

Publication date: Jun 10, 2019

The logistic advantages and advanced training capabilities of the G-EO System, as well as the benefits reported in other populations, support this strategy as a potentially potent rehabilitation tool for restoring and maintaining function in progressive Multiple Sclerosis (MS). This approach represents a paradigm shifting opportunity for improving current clinical practices for patients with progressive MS. If successful, this project will provide initial evidence for increasing patient access to the G-EO System, and this could be accomplished through “regional technology centers” using a rural health-delivery approach. There are several novel aspects of the proposed trial: (1) the examination of a novel gait rehabilitation stimulus (G-EO System) that could alter current clinical practices; (2) the focus on patients with progressive MS who have gait impairment (i.e., those who have received minimal research attention), which was recently described as the greatest therapeutic challenge facing the MS community; and (3) a study design that accounts for standard therapy. Specific Aims: The investigators designed a single-blinded, randomized pilot trial of electromechanically-assisted gait training using the G-EO System in patients with progressive MS with gait disability (EDSS=4.0-7.5). Specific Aim 1 will establish the safety and feasibility of gait training using the G-EO System. Specific Aim 2 will determine the efficacy of gait training using the G-EO System for improving mobility, symptomatic, quality of life, and participatory outcomes.

Concepts Keywords
Aim Medical specialties
Asymptomatic Multiple sclerosis
Bone 4-Aminopyridine
Cardiovascular Disease Gait training
Disability Terrestrial locomotion
Gait Walking
Indiana Physical therapy
Multiple Sclerosis MS
Paradigm Stable disease
Physical Therapy Multiple Sclerosis
Physician Organ systems
Progressive Animals
Stimulus

Semantics

Type Source Name
disease MESH Sclerosis
disease MESH Contraindications
drug DRUGBANK Dalfampridine
disease MESH cardiovascular disease
gene UNIPROT EHD1
disease DOID Secondary Progressive Multiple Sclerosis
disease MESH Secondary Progressive Multiple Sclerosis
disease MESH diagnosis
gene UNIPROT DNMT1
gene UNIPROT CD69
gene UNIPROT CD5L
gene UNIPROT EGR3
disease MESH community
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
disease MESH Gait

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *